Literature DB >> 22986146

Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium.

Darren R Brenner1, Paolo Boffetta, Eric J Duell, Heike Bickeböller, Albert Rosenberger, Valerie McCormack, Joshua E Muscat, Ping Yang, H-Erich Wichmann, Irene Brueske-Hohlfeld, Ann G Schwartz, Michele L Cote, Anne Tjønneland, Søren Friis, Loic Le Marchand, Zuo-Feng Zhang, Hal Morgenstern, Neonila Szeszenia-Dabrowska, Jolanta Lissowska, David Zaridze, Peter Rudnai, Eleonora Fabianova, Lenka Foretova, Vladimir Janout, Vladimir Bencko, Miriam Schejbalova, Paul Brennan, Ioan N Mates, Philip Lazarus, John K Field, Olaide Raji, John R McLaughlin, Geoffrey Liu, John Wiencke, Monica Neri, Donatella Ugolini, Angeline S Andrew, Qing Lan, Wei Hu, Irene Orlow, Bernard J Park, Rayjean J Hung.   

Abstract

To clarify the role of previous lung diseases (chronic bronchitis, emphysema, pneumonia, and tuberculosis) in the development of lung cancer, the authors conducted a pooled analysis of studies in the International Lung Cancer Consortium. Seventeen studies including 24,607 cases and 81,829 controls (noncases), mainly conducted in Europe and North America, were included (1984-2011). Using self-reported data on previous diagnoses of lung diseases, the authors derived study-specific effect estimates by means of logistic regression models or Cox proportional hazards models adjusted for age, sex, and cumulative tobacco smoking. Estimates were pooled using random-effects models. Analyses stratified by smoking status and histology were also conducted. A history of emphysema conferred a 2.44-fold increased risk of lung cancer (95% confidence interval (CI): 1.64, 3.62 (16 studies)). A history of chronic bronchitis conferred a relative risk of 1.47 (95% CI: 1.29, 1.68 (13 studies)). Tuberculosis (relative risk = 1.48, 95% CI: 1.17, 1.87 (16 studies)) and pneumonia (relative risk = 1.57, 95% CI: 1.22, 2.01 (12 studies)) were also associated with lung cancer risk. Among never smokers, elevated risks were observed for emphysema, pneumonia, and tuberculosis. These results suggest that previous lung diseases influence lung cancer risk independently of tobacco use and that these diseases are important for assessing individual risk.

Entities:  

Mesh:

Year:  2012        PMID: 22986146      PMCID: PMC3530374          DOI: 10.1093/aje/kws151

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  65 in total

1.  Intake of flavonoids and lung cancer.

Authors:  L Le Marchand; S P Murphy; J H Hankin; L R Wilkens; L N Kolonel
Journal:  J Natl Cancer Inst       Date:  2000-01-19       Impact factor: 13.506

2.  Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting.

Authors:  Richard M Peek; Suresh Mohla; Raymond N DuBois
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Insulation, asbestos, smoking habits, and lung cancer cell types.

Authors:  J E Muscat; S D Stellman; E L Wynder
Journal:  Am J Ind Med       Date:  1995-02       Impact factor: 2.214

4.  A rigorous and comprehensive validation: common genetic variations and lung cancer.

Authors:  Ping Yang; Yafei Li; Ruoxiang Jiang; Julie M Cunningham; Yan Li; Fang Zhang; Mariza de Andrade
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

5.  Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.

Authors:  Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta
Journal:  Chest       Date:  2007-12       Impact factor: 9.410

6.  Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark.

Authors:  Anne Tjønneland; Anja Olsen; Katja Boll; Connie Stripp; Jane Christensen; Gerda Engholm; Kim Overvad
Journal:  Scand J Public Health       Date:  2007       Impact factor: 3.021

7.  DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors.

Authors:  Irene Orlow; Bernard J Park; Urvi Mujumdar; Himali Patel; Puiki Siu-Lau; Brian A Clas; Robert Downey; Raja Flores; Manjit Bains; Nabil Rizk; Gemma Dominguez; Jen Jani; Marianne Berwick; Colin B Begg; Mark G Kris; Valerie W Rusch
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

8.  UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer.

Authors:  D R Baldwin; S W Duffy; N J Wald; R Page; D M Hansell; J K Field
Journal:  Thorax       Date:  2011-02-11       Impact factor: 9.139

9.  Lung cancer in a U.S. population with low to moderate arsenic exposure.

Authors:  Julia E Heck; Angeline S Andrew; Tracy Onega; James R Rigas; Brian P Jackson; Margaret R Karagas; Eric J Duell
Journal:  Environ Health Perspect       Date:  2009-07-02       Impact factor: 9.031

10.  The LLP risk model: an individual risk prediction model for lung cancer.

Authors:  A Cassidy; J P Myles; M van Tongeren; R D Page; T Liloglou; S W Duffy; J K Field
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

View more
  75 in total

1.  Deacetylation by SIRT1 Reprograms Inflammation and Cancer.

Authors:  Tie Fu Liu; Charles E McCall
Journal:  Genes Cancer       Date:  2013-03

Review 2.  Update in lung cancer and mesothelioma 2012.

Authors:  Charles A Powell; Balazs Halmos; Serge P Nana-Sinkam
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

Review 3.  Germline mutations predisposing to non-small cell lung cancer.

Authors:  Gerald H Clamon; Aaron D Bossler; Taher Abu Hejleh; Muhammad Furqan
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

Review 4.  Screening for lung cancer using low-dose computed tomography: concerns about the application in low-risk individuals.

Authors:  Jiu-Wei Cui; Wei Li; Fu-Jun Han; Yu-Di Liu
Journal:  Transl Lung Cancer Res       Date:  2015-06

5.  Improving CT screening for lung cancer with a highly predictive risk model.

Authors:  Cristiano Rampinelli; Marta Minotti
Journal:  Ann Transl Med       Date:  2018-04

6.  Fungal infection mimicking pulmonary malignancy: clinical and radiological characteristics.

Authors:  Marcos Duarte Guimarães; Edson Marchiori; Gustavo de Souza Portes Meirelles; Bruno Hochhegger; Pablo Rydz Pinheiro Santana; Jefferson Luiz Gross; Almir Galvão Vieira Bitencourt; Piyaporn Boonsirikamchai; Myrna Corbos Barco Godoy
Journal:  Lung       Date:  2013-09-17       Impact factor: 2.584

Review 7.  Lung cancer screening in patients with chronic obstructive pulmonary disease.

Authors:  Jessica Gonzalez; Marta Marín; Pablo Sánchez-Salcedo; Javier J Zulueta
Journal:  Ann Transl Med       Date:  2016-04

8.  Serum concentrations of club cell secretory protein (Clara) and cancer mortality in adults: a population-based, prospective cohort study.

Authors:  Stefano Guerra; Monica M Vasquez; Amber Spangenberg; Marilyn Halonen; Fernando D Martinez
Journal:  Lancet Respir Med       Date:  2013-11-15       Impact factor: 30.700

Review 9.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

10.  Lung Cancer Among Firefighters: Smoking-Adjusted Risk Estimates in a Pooled Analysis of Case-Control Studies.

Authors:  Carolina Bigert; Per Gustavsson; Kurt Straif; Dirk Taeger; Beate Pesch; Benjamin Kendzia; Joachim Schüz; Isabelle Stücker; Florence Guida; Irene Brüske; Heinz-Erich Wichmann; Angela C Pesatori; Maria Teresa Landi; Neil Caporaso; Lap Ah Tse; Ignatius Tak-Sun Yu; Jack Siemiatycki; Jérôme Lavoué; Lorenzo Richiardi; Dario Mirabelli; Lorenzo Simonato; Karl-Heinz Jöckel; Wolfgang Ahrens; Hermann Pohlabeln; Adonina Tardón; David Zaridze; John K Field; Andrea 't Mannetje; Neil Pearce; John McLaughlin; Paul Demers; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Rodica Stanescu Dumitru; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Paolo Boffetta; Susan Peters; Roel Vermeulen; Hans Kromhout; Thomas Brüning; Ann C Olsson
Journal:  J Occup Environ Med       Date:  2016-11       Impact factor: 2.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.